Targeting ER proteostasis with FDA approved drugs to improve outcome from SARSCoV-2 infection
- Funded by Academy of Finland
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Academy of FinlandPrincipal Investigator
Mikko AiravaaraResearch Location
FinlandLead Research Institution
Helsingin yliopistoResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable